Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2020 /PRNewswire/ -- Attralus, a biopharmaceutical company focused on creating transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, today announced clinical data from its ongoing Phase 1/2 trial assessing...

from PR Newswire: https://ift.tt/2VGp1Ul